NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Cyclerion Therapeutics Stock (NASDAQ:CYCN) Get Cyclerion Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$3.49▼$34.7252-Week Range N/AVolume435,914 shsAverage Volume96,117 shsMarket Capitalization$16.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need. The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction. In parallel, Cyclerion is advancing CY6463, a central nervous system-penetrant sGC stimulator, in neurocognitive and neurodegenerative disorders. Both programs are supported by preclinical and early-stage clinical data suggesting potential benefits in modulating cGMP signaling across multiple organ systems. Cyclerion leverages a modular research platform to optimize pharmacokinetic and pharmacodynamic properties for both systemic and brain-targeted therapies. Founded in May 2018 as a spin-out from Ironwood Pharmaceuticals, Cyclerion is headquartered in Cambridge, Massachusetts, with research collaborations and clinical sites spanning the United States and Europe. The company is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. Cyclerion continues to build on its translational science capabilities to expand its pipeline of sGC-based therapeutics and explore strategic partnerships to advance its programs toward regulatory milestones.AI Generated. May Contain Errors. Read More Cyclerion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreCYCN MarketRank™: Cyclerion Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 820th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCyclerion Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCyclerion Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cyclerion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cyclerion Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclerion Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclerion Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cyclerion Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.59% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 0.26, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently decreased by 65.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.59 News SentimentCyclerion Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cyclerion Therapeutics this week, compared to 1 article on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclerion Therapeutics' insider trading history. Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYCN Stock News HeadlinesKorsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 MillionSeptember 8, 2026 | globenewswire.comCyclerion Therapeutics (NASDAQ:CYCN) Shares Scheduled to Reverse Split on Wednesday, September 9thSeptember 5, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 12 at 1:00 AM | Awesomely (Ad)Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s PipelineApril 21, 2026 | finance.yahoo.comPenny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?April 2, 2026 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)April 2, 2026 | prnewswire.comCyclerion to combine with Korsana Biosciences in $380 million merger dealApril 2, 2026 | msn.comCyclerion provides public listing vehicle for Korsana in $380M dealApril 2, 2026 | bizjournals.comSee More Headlines CYCN Stock Analysis - Frequently Asked Questions How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its earnings results on Tuesday, May, 12th. The company reported ($5.32) EPS for the quarter, topping the consensus estimate of ($120.40) by $115.08. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative trailing twelve-month return on equity of 87.96%. When did Cyclerion Therapeutics' stock split? Cyclerion Therapeutics's stock reverse split before market open on Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Cyclerion Therapeutics' major shareholders? Top institutional shareholders of Cyclerion Therapeutics include ADAR1 Capital Management LLC (6.38%), Braidwell LP (3.35%) and BlackRock Inc. (0.36%). View institutional ownership trends. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), GE Aerospace (GE), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/12/2026Today9/12/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CYCN CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.53 million Net Margins-170.11% Pretax Margin-353.00% Return on Equity-87.96% Return on Assets-74.86% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual Sales$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / BookN/AMiscellaneous Outstanding Shares4,680,000Free Float3,075,000Market Cap$16.33 million OptionableNo Data Beta1.75 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CYCN) was last updated on 9/12/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...Investors Alley | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe retirement income that answers “yes” when everything else says noTodd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...Eagle Publishing | Sponsored17 Nobel Prize winners… one startling warningOn July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...Porter & Company | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | SponsoredI called NVDA at $6 - Here's what’s next…Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
